

Nithya Srinivas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/130793/publications.pdf>

Version: 2024-02-01

11
papers

201
citations

1307594

7
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

395
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2020, 4, 1656-1669.	5.2	68
2	Pharmacokinetics of antiretrovirals in mucosal tissue. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 893-905.	3.3	30
3	Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species. <i>Xenobiotica</i> , 2019, 49, 1192-1201.	1.1	30
4	Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1059-1074.	3.5	23
5	Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	15
6	Multimodal analysis of drug transporter expression in gastrointestinal tissue. <i>Aids</i> , 2017, 31, 1669-1678.	2.2	11
7	The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1022-1029.	2.0	9
8	Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	6
9	Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. <i>Clinical and Translational Science</i> , 2019, 12, 302-311.	3.1	5
10	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 523-534.	0.4	3
11	Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. <i>Clinical and Translational Science</i> , 2021, 14, 784-790.	3.1	1